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Christine Hinz, PhD; You Zhou, PhD; Julie Williams, PhD; Maceler Aldrovandi, PhD; William J. Watkins, PhD;  
Adam J. Engler , PhD; Valentina Lo Sardo , PhD; David A. Slatter , PhD; Stuart M. Allen, PhD; Jay Acharya, PhD;  
Jacquie Mitchell, MSc; Jackie Cooper, MSc; Junken Aoki, PhD; Kuniyuki Kano , PhD;  
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BACKGROUND: Common chromosome 9p21 single nucleotide polymorphisms (SNPs) increase coronary heart disease risk, 
independent of traditional lipid risk factors. However, lipids comprise large numbers of structurally related molecules not 
measured in traditional risk measurements, and many have inflammatory bioactivities. Here, we applied lipidomic and genomic 
approaches to 3 model systems to characterize lipid metabolic changes in common Chr9p21 SNPs, which confer ≈30% 
elevated coronary heart disease risk associated with altered expression of ANRIL, a long ncRNA.
METHODS: Untargeted and targeted lipidomics was applied to plasma from NPHSII (Northwick Park Heart Study II) 
homozygotes for AA or GG in rs10757274, followed by correlation and network analysis. To identify candidate genes, 
transcriptomic data from shRNA downregulation of ANRIL in HEK-293 cells was mined. Transcriptional data from vascular 
smooth muscle cells differentiated from induced pluripotent stem cells of individuals with/without Chr9p21 risk, nonrisk 
alleles, and corresponding knockout isogenic lines were next examined. Last, an in-silico analysis of miRNAs was conducted 
to identify how ANRIL might control lysoPL (lysophosphospholipid)/lysoPA (lysophosphatidic acid) genes.
RESULTS: Elevated risk GG correlated with reduced lysoPLs, lysoPA, and ATX (autotaxin). Five other risk SNPs did not 
show this phenotype. LysoPL-lysoPA interconversion was uncoupled from ATX in GG plasma, suggesting metabolic 
dysregulation. Significantly altered expression of several lysoPL/lysoPA metabolizing enzymes was found in HEK 
cells lacking ANRIL. In the vascular smooth muscle cells data set, the presence of risk alleles associated with altered 
expression of several lysoPL/lysoPA enzymes. Deletion of the risk locus reversed the expression of several lysoPL/
lysoPA genes to nonrisk haplotype levels. Genes that were altered across both cell data sets were DGKA, MBOAT2, 
PLPP1, and LPL. The in-silico analysis identified 4 ANRIL-regulated miRNAs that control lysoPL genes as miR-186-
3p, miR-34a-3p, miR-122-5p, and miR-34a-5p.
CONCLUSIONS: A Chr9p21 risk SNP associates with complex alterations in immune-bioactive phospholipids and their 
metabolism. Lipid metabolites and genomic pathways associated with coronary heart disease pathogenesis in Chr9p21 and 
ANRIL-associated disease are demonstrated.
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The association of altered plasma lipids with coro-nary heart disease (CHD) risk has been known for decades, however, for some CHD-risk single nucleo-
tide polymorphisms (SNPs), there is no association with 
traditional lipid measurements, such as lipoproteins (HDL 
[high-density lipoprotein] or LDL [low-density lipopro-
tein]) or their constituents: cholesteryl esters and triglyc-
erides.1 As a prominent example, the relatively common 
CDKN2A/2B (rs10757274, A>G; minor allele frequency 
=0.48) SNP on chromosome 9p21 confers ≈30% ele-
vated risk of CHD but acts independently of traditional 
lipid risk factors.1 Chr9p21 SNPs, including rs10757274, 
are believed to alter disease risk through modulation of the 
long noncoding (lnc)RNA, ANRIL, although both up and 
downregulation has been associated with risk (see dis-
cussion for more detail).2,3 ANRIL isoforms are detected 
in peripheral blood cells, aortic smooth muscle, endothe-
lial cells, and heart, and SNPs in Chr9p21 are associated 
not only with CHD but also numerous cancers.2,4–6 Cel-
lular studies show that ANRIL lncRNA downregulates the 
tumor suppressors CDKN2A/2B by epigenetic regula-
tion, modulating expression of pathways involved in dif-
ferentiation, apoptosis, matrix remodeling, proliferation, 
apoptosis, senescence, and inflammation.5,7 Whether or 
how the entire CHD-risk region or ANRIL regulates bio-
active lipids is currently unknown.
Lipids represent thousands of diverse molecules. 
However, CHD clinical risk algorithms such as Fram-
ingham or QRISK include circulating lipoproteins only.8,9 
Importantly, bioactive lipids that regulate vascular inflam-
mation/proliferation in line with the function of ANRIL 
and thus may be directly relevant to Chr9p21-medi-
ated CHD are not included in these measures. Indeed, 
whether ANRIL mediates its effects via an impact on 
bioactive lipid signaling has not been examined and was 
studied herein using lipidomics.
Here, plasma from a prospective cohort (NPHSII 
[Northwick Park Heart Study II]), which recruited ≈3000 
men aged 50 to 64 years clinically free of CHD from 
1990 to 1991, was analyzed using targeted and untar-
geted lipidomics, followed by validation, metabolic corre-
lation, and network analysis.10,11 Then, gene transcription 
for lipid metabolic enzymes was mined in data from a cel-
lular ANRIL knockdown study and from vascular smooth 
muscle cells differentiated from induced pluripotent stem 
cells obtained from individuals with/without Chr9p21 
risk, nonrisk (NN) alleles, and corresponding isogenic 
lines deleted of the entire CHD locus.12,13 Database min-
ing for potential candidate miRNAs linking ANRIL with 
gene expression was conducted. The study reveals novel 
insights into the potential role of key bioactive signaling 
lipids in this common but poorly understood form of CHD.
METHODS
The authors declare that all supporting data are available within 
the article (and its Data Supplement). Ethical approval for the 
use of NPHSII samples was provided by the National Hospital 
for Neurology and Neurosurgery and the Institute of Neurology 
Joint Research Ethics Committee, and Joint UCL/UCLH 
Committee of Human Research, Committees A and Alpha, and 
all samples were obtained with informed consent. Full methods 
are provided in Materials in the Data Supplement.
RESULTS
Global Lipidomics Demonstrates That LysoPLs 
Are Reduced in GG Plasma Versus AA
To capture all lipids (knowns/unknowns), high-resolution 
Orbitrap MS data from long chromatographic separations 
were analyzed using XCMS, then processed for cleanup/
assignment to LIPID MAPS categories, using LipidFinder 
(Figure 1A and 1B).14 Plasma quality was checked through 
careful comparison with fresh plasma, detailed in Materi-
als in the Data Supplement. Most lipid categories were 
unchanged, however, oxidized phospholipids and lysoPCs 
had elevated somewhat in storage (Figures I through III 
in the Data Supplement). This is not unexpected, and we 
include a full discussion of this phenomenon in Materi-
als in the Data Supplement. To assess the impact of the 
rs10757274, A>G SNP, we compared AA (n=39) with 
the risk genotype GG (n=33). Data were analyzed first 
using the Mann-Whitney U test, then chromatograms for 
all features with P<0.075 were manually checked for qual-
ity. LipidFinder detected 1878 lipids, with 872 assigned to 
a category (Figure 1B). Next, quantile normalization was 
applied followed by the Mann-Whitney U test, and then a P 
value adjustment using sequential goodness of fit metatest 
to each subclass.15 The sequential goodness of fit metatest 
has been shown as especially well-suited to small sample 
sizes when the number of tests is large. This data is shown 
in volcano plots in Figure 1C through 1J, and the P values 
are in column M (Tabs I and II in the Data Supplement). 
Nonstandard Abbreviations and Acronyms
ATX autotaxin
CHD coronary heart disease
GPCR G protein-coupled receptor
HDL high-density lipoprotein
LDL low-density lipoprotein
lysoPAs lysophosphatidic acids
lysoPLs lysophosphospholipids
NN nonrisk
NNWT controls
NPHSII Northwick Park Heart Study II
PAF platelet-activating factor
RRWT risk haplotypes
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Figure 1. Global lipidomics reveals class-specific changes in glycerophospholipids (GPLs) in rs10757274 GG vs AA.
A, Scatterplot of features in a plasma sample (≈14 000) after processing high-resolution MS data using XCMS. Analysis was undertaken using 
parameters provided in Materials in the Data Supplement. B, Scatterplot obtained after LipidFinder and manual-data clean-up, as described 
in Methods. Each dot represents a lipid described by m/z value and retention time. Putative identification and assignment of category were 
performed using WebSearch of the curated LIPID MAPS database. C–J, Volcano plots show differences in lipid classes with genotype. 
Volcano plots were generated as described in Methods, plotting log2(fold change) vs −log10(P value) for all (n=39 AA and 33 GG), following 
P value adjustment using sequential goodness of fit metatest (SGoF).
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Those most affected by genotype were glycerophospholip-
ids and unknowns (Figure 1C through 1J, Table 1). Follow-
ing P value adjustment the number of significantly different 
lipids was 17, with 7 putatively identified as lysoPC ions 
and adducts (Tabs I and II in the Data Supplement). An 
additional group of 8 had P values close to significance 
at 0.05 to 0.08. All were reduced in GG plasma. As this 
method is used as for hypothesis generation only, we next 
validated our results using gold-standard quantitative tar-
geted methods.
Quantitative Targeted Lipidomics Confirms 
Decreased LysoPLs in the GG Samples
The same plasmas were analyzed using a targeted fully 
quantitative assay for 15 lysoPLs (lysophosphospholip-
ids). Of these several lysoPCs significantly decreased, with 
both lysoPC and lysoPEs all trending towards lower lev-
els in GG (Figure IVA in the Data Supplement). This was 
replicated using new samples from NPHSII (n=47: AA, 
49: GG; Figure IV in the Data Supplement). When both 
data sets were combined (n=82−86/group), all 8 lysoPCs 
were significantly lower in the GG genotype (Figure 2A). 
Thus, lysoPLs are overall suppressed in the GG genotype, 
with a more robust effect on lysoPCs than lysoPEs.
Significantly Altered LysoPLs Are Not Detected 
in 5 Additional CHD Risk-Altering SNPs
LipidFinder data were analyzed for additional SNPs from 
the NPHSII cohort, comparing subjects homozygous for 
the common alleles with subjects homozygous for rare 
protective alleles for SORT1, LDLR or APOE E2/E2, or 
rare risk alleles APOA5 or APOE4/E4 (Table I in the 
Data Supplement). For most lysoPLs, levels were not sig-
nificantly altered, with the exception of one for APOA5 
(upregulated, lysoPE(18:1), and one for LDLR [down-
regulated, lysoPC(18:2)]; Figure 2B). This indicates that 
lysoPLs are consistently reduced only in the GG risk 
SNP rs10757274.
The Plasma LysoPA/ATX Axis Is Dysregulated 
in the GG Group
Next, lysoPL-related metabolites/enzymes were mea-
sured. Metabolism of lysoPL to lysoPA (lysophospha-
tidic acid) in healthy plasma can be mediated by ATX 
(autotaxin).16 Here, we used a targeted liquid chroma-
tography-tandem mass spectrometry assay for lysoPAs 
and an immunoenzymatic assay for ATX. ATX was sig-
nificantly decreased (P=0.026). Based on power calcu-
lations (Material in the Data Supplement), an additional 
set of plasmas was included to increase sample num-
bers to 95 to 100 per group for lysoPAs. Liquid chro-
matography-tandem mass spectrometry demonstrated 
overall small reductions but with several being signifi-
cantly lower (Figure 2C and 2D). Taken with the lysoPL 
data, this indicates a global suppression of lysoPL/
lysoPA/ATX metabolic pathway in the GG group.
Next, correlation analysis was undertaken to exam-
ine the contribution of ATX in metabolizing lysoPL 
to lysoPA. In AA plasmas, ATX showed very weak 
positive or negative correlations with total lysoPL or 
lysoPA, respectively (Figure 3A and 3B). This agrees 
with reports that ATX contributes to lysoPL conver-
sion to lysoPA in healthy subjects.16 In contrast, in GG 
plasmas, these weak trends were somewhat reversed 
(Figure 3C and 3D). To look in more depth, we corre-
lated substrates with products (Figure 3E through 3H). 
In the AA group, significant positive correlations were 
seen for total lysoPA with lysoPL (P=0.034). Compar-
ing lipids with the same fatty acyl, significant correla-
tion was seen between lysoPA(18:2) and lysoPL(18:2) 
(P=0.023; Figure 3E and 3F). This indicates that as the 
pool of lysoPL increases, the level of lysoPA increases 
in parallel, and this would be consistent with conversion 
by ATX. This relationship was fully reversed in the GG 
group, where total lysoPL, lysoPL(18:2), or lysoPL(20:4) 
were negatively correlated with their corresponding 
lysoPAs (P=0.019, 0.054, and 0.019, respectively; Fig-
ure 3G through 3I). We next analyzed correlation slopes 
for AA versus GG, comparing either lysoPL:lysoPA (Fig-
ure 3E versus Figure 3G), or lysoPL(18:2):lysoPA(18:2) 
(Figure 3F versus Figure 3H). Both these comparisons 
revealed significant differences (P=0.0264 and 0.0029, 
respectively).17 These data confirm altered metabolism 
of lysoPL and lysoPA lipids between genotypes. Spe-
cifically, conversion of lysoPL to lysoPA appears to be 
suppressed in the GG homozygotes.
The direct contribution of ATX to metabolizing lysoPL 
to lysoPA was next examined by correlating normalized 
ratios of lysoPC(18:2):lysoPA(18:2) with ATX. In this 
comparison, we expect that as ATX increases, the ratio 
of substrate:product would reduce due to their intercon-
version. For AA plasma, a weak negative correlation was 
seen (Figure 3J). In contrast, a significant positive cor-
relation was observed for GG plasma (Figure 3K). Thus, 
as ATX increases, a higher ratio of substrate:product 
Table 1. Number of Detected and Identified Lipid Features in the Global Lipidomics Assay
Lipid Class FA GPL GL SL Sterol Prenol Unknowns Total
Detected (P<0.05 after SGoF) 51 (0) 220 (0) 401 (13) 166 (2) 27 (1) 7 (0) 1006 (1) 1878 (17)
The number of lipids in each class is shown, with the number of significantly different lipids (nonparametric 1-tailed Mann-Whitney U test, assuming unequal 
variance with a threshold of P≤0.05, after SGoF correction), between the SNP group and controls shown in parentheses. FA indicates fatty acyl; GL, glycerolipid; GPL, 
glycerophospholipid; SGoF, sequential goodness of fit metatest; SL, sphingolipid; and SNP, single nucleotide polymorphism.
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Figure 2. LysoPLs (Lysophosphospholipids) are significantly reduced in rs10757274 GG but not in subjects with unrelated SNPs.
A, Several LPCs are lower in GG samples than AA controls, and LPEs trend towards lower levels. LysoPLs were determined using LC/MS/MS 
as described in Methods (n=88 AA and 81 GG). Tukey box plot, *P<0.05, **P<0.01, ***P<0.005, 2-tailed, unpaired Student t test (black) and 
Mann-Whitney U (red). B, Plasma lysoPL are not altered by other risk SNPs. Plasma from the NPHSII (Northwick Park Heart Study II) cohort 
containing several risk (up or down) SNPs were analyzed using LipidFinder, and m/z values corresponding to lysoPL extracted and compared. 
These are plotted on a volcano plot, to show fold change vs significance, following P value adjustment using sequential goodness of fit metatest 
(SGoF). Numbers and genotypes are shown in Table I in the Data Supplement. C, ATX (Autotaxin) is significantly decreased in GG samples 
compared with AA controls. Plasma ATX activity was measured as described in Methods (n=47 AA and 49 GG). D, LysoPAs (Lysophosphatidic 
acids) are significantly decreased in GG plasma compared with AA controls. Plasma lysoPAs were measured as described in Methods, using 
LC/MS/MS (n=95 AA and 100 GG). Tukey box plot, *P<0.05, **P<0.01, ***P<0.005, 2-tailed, unpaired Student t test (black). LC/MS/MS 
indicates liquid chromatography-tandem mass spectrometry; and SNP, single nucleotide polymorphism.
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Figure 3. The lysoPL (lysophosphospholipids)/lysoPA (lysophosphatidic acid)/ATX (autotaxin) axis is dysregulated in the GG 
plasmas, while the profile of molecular species is unchanged for lysoPL/lysoPA.
A–D, ATX shows altered correlations with plasma lysoPL or lysoPA in GG vs AA plasma. Levels of lysoPL or lysoPA quantified by LC/MS/MS 
in the validation cohort were correlated using Answerminer, to determine Pearson correlation coefficient. A and B, AA control plasma, (C and 
D) GG risk plasma (n=47 AA and 49 GG). E–I, LysoPL and lysoPA are positively correlated for AA plasma, (Continued )
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was seen in GG, suggesting a decoupling of ATX from 
metabolizing lysoPL to lysoPA. Comparing the slopes 
for AA versus GG revealed significant differences based 
on genotype (P=0.0157). This further underscores the 
dysregulation of the lysoPL metabolic pathway in the 
GG group and suggests that non-ATX pathways may 
mediate lysoPL to lysoPA conversion. Last, the relative 
ratios of all lysoPL and lysoPA molecular species were 
unchanged in the GG versus AA groups (Figure 3L). Thus, 
while metabolism of lysoPL/lysoPA by ATX is altered, 
there was no influence of genotype on molecular com-
position overall. Notably, ATX preferentially metabolizes 
unsaturated lysoPCs.18 Overall, despite the correlations 
only showing associations, when taken with our observa-
tions that plasma from GG subjects has significantly less 
ATX protein and that all lysoPC molecular species are 
similarly affected, our data strongly evidence that there 
is less involvement of ATX in metabolizing these lipids in 
GG plasmas.
Next, a Pearson correlation analysis looking at rela-
tionships between individual lipids and ATX was next 
undertaken using Cytoscape. For thresholds, the clas-
sification system of Schober was used.19 Here, we see 
that there are moderate (r=0.40–0.69, green) or strong 
(r=0.70–1.00 gray) correlations between lipids of the 
same class, while there are weak (r=0.10–0.39, red) 
correlations between different lipid classes (Figure 4A). 
Importantly, the key difference in the data set is that the 
weak correlations between classes are positive for the 
AA group, while they are negative for the GG group (Fig-
ure 4A). Overall, this indicates that these lipids behave 
similarly within AA subjects. In contrast, in GG plasma, 
while lipid classes still positively correlate within their 
groups (eg, lysoPCs correlate strongly with each other), 
the links between lysoPL and lysoPA are lost. Instead 
correlations were weakly negative between lysoPE and 
lysoPA (Figure 4A). As in Figure 4, ATX weakly positively 
correlates with lysoPA in the AA group but instead with 
lysoPL in the GG group. This analysis reinforces our find-
ings of altered metabolism for lysoPL/lysoPA but here at 
the level of individual lipid species.
ANRIL Knockdown Significantly Alters Lipid and 
LysoPL Metabolism Gene Expression
Chr9p21 risk SNPs are believed to act via altering expres-
sion of ANRIL, which regulates cell proliferation/senes-
cence in vitro.2,4,5 To examine for a functional link with 
lysoPL/lysoPA metabolism, we analyzed the effect of 
shRNA downregulation of the proximal ANRIL transcripts 
EU741058 and DQ485454 in HEK-293 cells at 48 and 
96 hours.12 A GO analysis found significant alterations of 
several lipid pathways by ANRIL, including Regulation of 
Lipid Metabolic Processes (GO: 0019216), Phospholipid 
Metabolic Processes (GO:0006644), Cellular Lipid Meta-
bolic Process (GO:0044255), and Lipid Biosynthetic Pro-
cesses (GO:0008610), for example, Regulation of Lipid 
Metabolic Processes was 1.9- or 1.88-fold enriched (false 
discovery rate <0.05, Benjamini-Hochberg), respectively, at 
48 and 96 hours, respectively (Table 2, Tabs III and IV in 
the Data Supplement). Thus, large numbers of lipid-associ-
ated genes were significantly differentially regulated (Tabs 
V and VI in the Data Supplement).
We next examined the effect of ANRIL knockdown 
on 49 candidate lysoPL metabolism genes (Tab VII in 
the Data Supplement). Of these, 9 were significantly 
changed at both time points and another 6 at a single 
timepoint (Table 3). Several were consistent with lowered 
lysoPL/lysoPA, including reduced PNPLA2, PLA2G4C, 
increased LPCAT2, MBOAT2, ACSL6, PLBD1, PLPP1, 
PLPP2, and PLPPR2 (Table 3, Figure 4B and 4C). Addi-
tional relevant genes were regulated, but in the opposing 
direction, including decreased LPCAT1 and LPCAT3 and 
increased LPL, PLA2G7, and DGKA (Table 3). ENPP2 
(the gene encoding ATX) was significantly increased 
by ANRIL suppression (Table 3, Figure 4B). This data 
is displayed in volcano plots of the full Affymetrix data 
set (Figure 4B and 4C and Figure V in the Data Sup-
plement). Genes in red represent significantly different 
lysoPL metabolizing genes from the lipid GO pathways.
Vascular Smooth Muscle Cells Generated From 
Induced Pluripotent Stem Cells From Chr9p21 
Risk Haplotypes Show Altered Expression of 
LysoPL Metabolism Genes and Correlation of 
Expression With ANRIL Isoform Expression
Vascular smooth muscle cells (VSMCs) generated by 
differentiation of induced pluripotent stem cells from 
humans homozygous for risk haplotypes in Chr9p21 
show globally altered transcriptional networks, dys-
regulated adhesion, contraction, and proliferation, with 
deletion of the risk haplotype rescuing the phenotype.13 
Here, we interrogated an RNAseq data set of mature 
iPSC-derived VSMCs for expression of the 49 lysoPL 
metabolism genes (Tab VIII in the Data Supplement). 
Examination of individual genes revealed 14 that were 
Figure 3 Continued. but negatively correlated for GG. The sum of all lysoPAs or lysoPLs in each set were correlated using Answerminer, 
as above (E and G). Alternatively, lipids containing 18:2 or 20:4 were separately correlated (F, H, and I). E and F, AA control plasma, (G, 
H, and I) GG risk plasma (n=47 AA, 49 GG). J and K, The lysoPA(18:2)/lysoPL(18:2) ratio positively correlates with ATX in AA plasma, but 
negatively for GG, indicating a block in substrate:product conversion in GG. Correlations were performed using Answerminer (n=47 AA and 
49 GG). J, AA plasma, (K) GG plasma. P<0.05 indicates significant using the Pearson correlation test. L, The profile of individual lysoPL 
or lysoPA molecular species is unchanged between GG and AA plasmas. Levels of individual lysoPL/lysoPA were compared across both 
groups and shown as %. LC/MS/MS indicates liquid chromatography-tandem mass spectrometry.
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Figure 4. Cytoscape analysis of lipids reveals divergent metabolism in GG vs AA, while ANRIL knockdown is associated with 
significant changes to lysoPL (lysophosphospholipids)/lysoPA (lysophosphatidic acid)-metabolizing genes.
A, Cytoscape reveals strong links within related families, but a positive-negative switch for lysoPL-lysoPA correlations between AA-
GG plasmas. Pearson correlation networks were generated for the AA and GG validation samples (n=47 AA and 49 GG), using lipid 
concentrations. Nodes are colored by lipid sub-category and represent individual molecular species, and edges represent the correlation. 
Edges detail the Pearson correlation coefficients between nodes (lipids), where the width of the edge denotes value. Additionally, edges are 
colored by value: red (r=0.10–0.39); green (r=0.40–0.69); gray (r=0.70–1.00). (Continued )
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significantly different between risk haplotypes (RRWT) 
and other lines, and where removal of the risk locus in 
RR led to partial or complete rescue: ACSL3, DGKA, 
PLA2G2A, LPCAT2, LPL, PLA2G3, PLPPR2/LPPR2, 
PLA2G12A, PLPP1/PPAP2A, LCAT, PLA2G6, ACSL1, 
MBOAT2, and PNPLA3 (Figure 5A, Figure VI in the Data 
Supplement). Of these, DGKA, PLA2G12A, and LCAT 
were regulated in line with reduced lysoPC/lysoPA.
Multivariate analysis using principal component analy-
sis for expression of these 14 genes shows clear sepa-
ration of VSMC lines containing the RRWT from controls 
(NNWT) in PC-1 (Figure 5B). When the risk locus was 
deleted, the resulting RRKO cell lines instead clustered 
closer to NNWT and NNKO in PC-1 (Figure 5B). This 
analysis indicates that expression of several lysoPL 
metabolizing genes is different in risk haplotype cells but 
reverts closer to NN on removal of the 9p21 locus.
Next, correlations of genes that metabolize lysoPLs 
with ANRIL isoforms (exons 6–7 and 18–19) were per-
formed. Deletion of the Chr9p21 locus in the KO VSMC 
lines starts around exon 9 and runs downstream to the 
end of the coronary artery disease region.13 Analysis 
of ANRIL was performed by qPCR detection of ANRIL 
isoforms containing exons 6 and 7 (present in long and 
short isoforms) and exons 18 to 19 (in long isoforms 
only). The analysis showed a significant increase of iso-
forms containing exons 6 and 7 in RRWT cells, compared 
with NNWT cells (Figure VII in the Data Supplement), as 
previously described.13 ANRIL expression was minimal 
in NNWT, with levels comparable to a residual expres-
sion of ANRIL detected in both KO lines, possibly due to 
transcription of truncated transcripts. ANRIL analysis per-
formed using detection of exons 18 and 19 showed no 
significant differences between RRWT and NNWT cells. 
No transcript expression was detected in KO lines as 
expected because the deletion encompasses the last 10 
exons of the ANRIL gene. These analyses confirmed that 
ANRIL short isoforms containing exons 6 and 7 but not 
18 and 19 are upregulated in RRWT VSMCs. To evalu-
ate possible correlations between lysoPLs-related genes 
and ANRIL expression, all samples were used for ANRIL 
(exons 6–7) analysis, while for correlations with ANRIL 
(exons 18–19), only WT (RR and NN) were tested. Circu-
lar ANRIL isoforms have not been detected in these cells.
ANRIL (Exons 6–7)
Several genes correlated significantly, either in a positive or 
a negative direction with these ANRIL isoforms (Figure VIII 
in the Data Supplement). RRWT samples (in red) clustered 
together as groups, separated from all other samples, which 
were seen to express phospholipid (PL) metabolism genes 
similarly. This was somewhat expected because these PL 
metabolism genes were differently expressed in RRWT 
versus RRKO, NNWT, NNKO, as shown for ANRIL (6–7) 
expression (Figure 5B, Figure VII in the Data Supplement). 
However, the significant Pearson correlations between 
ANRIL (exons 6–7), and the individual genes show a direct 
association between this form of these ANRIL isoforms 
and some lysoPL genes.
ANRIL (Exons 18–19)
Here, correlations were tested using RRWT or NNWT 
clones separately and then compared. Five genes 
were identified where a significant negative correla-
tion between ANRIL (18–19) and lysoPL gene expres-
sion was seen (PNPLA3, DGKA, ENPP2, LPCAT3, and 
PLA2G4C) in the RR clones. In contrast, correlations in 
NN samples were weaker and not significant (Figure IX in 
the Data Supplement). This suggests an impact of ANRIL 
(18–19) isoforms on gene expression, that is absent/
reduced in NN. One NN clone displayed higher levels of 
ANRIL (18–19) compared with others, and as an outlier 
had a large impact on the correlation, reducing statistical 
power.
In Silico Analysis of miRNA Databases 
Suggests Potential Candidates for ANRIL 
Regulation of LysoPL Gene Expression
ANRIL displays sponge activity towards miRNAs.20 
To examine whether this could mechanistically link 
ANRIL with lysoPL gene expression, we undertook an 
in-silico analysis using 2 databases (including one that 
is experimentally validated: TarBase v8 (http://caro-
lina.imis.athena-innovation.gr/diana_tools/web/index.
php?r=tarbasev8%2Findex) and TargetScan (*http://
www.targetscan.org/vert_72/). We searched whether 
miRNAs known to be inhibited by ANRIL interact with 
PL-metabolizing genes that are altered in HEK or 
VSMC data sets. Here, the expected outcome is that 
target genes should be regulated in the same direction 
as ANRIL. Some hits were found, including 2 that were 
conserved across both data sets. In the HEK data, the 
miRNAs that interact with downregulated genes were 
miR-186-3p, miR-34a-3p (LPCAT1) and miR-122-5p, 
miR-34a-5p (LPCAT3). In the VSMC data set, where 
ANRIL (exons 6–7) is significantly upregulated in RR, we 
focused on genes that were elevated in RR and reduced 
Figure 4 Continued. C and D, Significant changes in lipid regulatory gene expression are observed with ANRIL knockdown in cell culture. 
Affymetrix array data generated in Congrains et al5 was analyzed using GO as described in Methods. Volcano plot showing differential gene 
expression of all genes on the Affymetrix HuGene1.0 v1, chip. LysoPL/lysoPA regulating genes that alter in line with decreased levels of the 
lipids in GG plasma are labeled. The horizontal dashed line shows where adj. P value <0.05 (Benjamini-Hochberg correction) where points 
(genes) above this line are significantly differentially expressed. LysoPL-regulating genes that alter in line with decreased levels of the lipids are 
labeled in black. Genes in red are annotated to the GO term detailed in the plot title. Data are plotted in R using ggplot2. B, Forty-eight hour 
shRNA knockdown. C, Ninety-six hour shRNA knockdown.
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when the locus was deleted. Here, we found miR-34a-5p 
(PLA2G6) and miR-122-5p (PNPLA3). These hits were 
all from the experimentally validated database (Tarbase) 
and differences in the target genes impacted may be due 
to the different cell types used.
DISCUSSION
Lipidomics MS is increasingly applied to prospective 
CHD cohorts that contain no genetic information, while 
conversely GWAS studies have examined associations 
with traditional lipid measures only (eg, total cholesterol or 
triglycerides).21–35 Cohorts are only now starting to exam-
ine the association of individual lipid molecular species 
with specific risk SNPs, and little information on this is 
yet available. Cohort lipidomics is an area that is increas-
ing in popularity, however, there are some serious pitfalls 
with using only untargeted methods. Including a high 
degree of validation, we show that a common Chr9p21 
(rs10757274, A>G) CHD-risk SNP is associated with 
Table 2. Several Lipid Related Gene Ontology Pathways Are Significantly Regulated by ANRIL Silencing in HEK-293 Cells
GO Biological Process
No. of Significantly 
Different Genes
GO Term Fold 
Enrichment P Value FDR
48 h shRNA knockdown 
vs control
Glycosphingolipid metabolic process 
(GO:0006687)
14 3.05 5.68×10−04 3.12×10−02
Regulation of lipid metabolic process 
(GO:0019216)
46 1.9 1.12×10−04 9.22×10−03
Phospholipid metabolic process (GO:0006644) 51 1.85 9.16×10−05 7.99×10−03
Cellular lipid metabolic process (GO:0044255) 109 1.68 6.07×10−07 1.37×10−04
Lipid metabolic process (GO:0006629) 130 1.61 5.02×10−07 1.19×10−04
Response to lipid (GO:0033993) 84 1.53 2.59×10−04 1.74×10−02
96 h shRNA knockdown 
vs control
Regulation of lipid metabolic process 
(GO:0019216)
74 1.88 2.80×10−06 3.38×10−04
Phospholipid metabolic process (GO:0006644) 73 1.63 2.05×10−04 1.30×10−02
Lipid biosynthetic process (GO:0008610) 102 1.61 1.54×10−05 1.51×10−03
Cellular lipid metabolic process (GO:0044255) 164 1.56 2.74×10−07 4.70×10−05
Lipid metabolic process (GO:0006629) 203 1.54 1.61×10−08 3.79×10−06
Results are from the PANTHER over-representation test, term enrichment service (pantherdb.org), using default analysis parameters (Fisher exact test with FDR 
P<0.05, Benjamini-Hochberg). Fold enrichment represents the number of observed differentially expressed genes with the GO annotation of interest, relative to genome 
background. The full list of genes significantly altered in these GO processes is provided in the Data Supplement, along with a list of all significantly altered GO processes 
at both timepoints. Note that FDR has no unit, while fold enrichment is a ratio with no unit. FDR indicates false discovery rate.
Table 3. Several LysoPL Relevant Genes Are Significantly Altered in ANRIL Knockdown
Predicted Effect on LysoPL(↓) 
on LysoPA(↓) Gene Name
48 Hour, Knockdown vs Control 96 Hour, Knockdown vs Control
Log2 Fold Change in 
Gene Expression
Adjusted  
P Value
Log2 Fold Change in 
Gene Expression
Adjusted  
P Value
↓↑ ENPP2 1.249 7.50×10−03 1.483 4.65×10−05
↓ LPCAT2 0.212 1.95×10−02 NS NS
↓ MBOAT2 NS NS 0.289 3.28×10−03
↓ ACSL6 0.283 0.0017 0.519 5.31×10−06
↓ PLA2G4C −0.351 0.0266 −0.356 0.016
↓ PNPLA2 −0.447 0.000031 −0.666 2.53×10−07
↓ PLBD1 0.368 0.0263 0.5036 0.00217
↓ PLPP1 NS NS 0.1637 0.049
↓ PLPP2 0.258 0.00137 0.2940 4.65×10−05
↓ PLPPR2 0.1136 0.0792 0.124 0.0101
↑ PLA2G7 0.611 0.000225 0.439 0.0016
↑ LPCAT1 −0.257 0.025 NS NS
↑ DGKA 0.247 0.00724 0.403 9.98×10−05
↑ LPL NS NS 0.230 0.0429
↑ LPCAT3 NS NS −0.298 0.0013
Data were analyzed using the oligo and limma packages in Bioconductor, see methods. P value was corrected for multiple testing using 
Benjamini-Hochberg (adjusted P value cutoff: 0.05), note there are no units for P value, and log2fold change is a ratio. LysoPA indicates 
lysophosphatidic acid; LysoPL, lysophosphospholipids; and NS, non significant.
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 3, 2020
Meckelmann et al Phospholipids Define a Cardiovascular Risk SNP
Circ Genom Precis Med. 2020;13:e002806. DOI: 10.1161/CIRCGEN.119.002806 June 2020 159
Figure 5. VSMCs from risk haplotypes show differential gene expression of lysoPL (lysophosphospholipid) metabolizing genes 
that are rescued by deletion of the Chr9p21 locus.
A, PCA shows that the presence of risk haplotypes is associated with differential gene expression of lysoPL genes. Induced pluripotent 
stem cells from peripheral monocytes were obtained and differentiated as described in Materials in the Data Supplement. RNAseq data 
were clustered using lysoPL metabolizing genes by PCA in R. Nonrisk haplotype (NNWT), risk haplotype (RRWT) and their genome edited 
counterparts (NNKO and RRKO) are shown. B, Example data sets for ACSL3 and DGKA, showing that removing the risk locus reverts 
gene expression back to levels in nonrisk individuals. *P<0.05, **P<0.01, ***P<0.005, Students t test, n=9–10 clones per group. C and D, 
Schematics showing impact of ANRIL silencing or risk haplotypes on relevant lysoPL metabolizing genes. PCA indicates principal component 
analysis; PC1, principal component-1; and VSMCs, vascular smooth muscle cells.
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metabolic alterations to the lysoPL/lysoPA/ATX axis in 
human plasma (Figures 1 through 4). This revealed a gen-
otype-specific change that was absent in 5 other GWAS-
proven CHD-risk SNPs. Since the action of rs10757274 
GG is independent from traditional lipid measurements, 
it may represent a different component of the disease, 
characterized, in part, by changes to bioactive signaling 
PLs, rather than storage/energy lipid pools.1
LysoPLs have an emerging role in cardiovascular dis-
ease that is not yet understood. In vitro, they mediate 
GPCR (G protein-coupled receptor) signaling that causes 
immune cell migration and apoptosis. This has led them 
to be proposed as proinflammatory.36–40 However, this is 
disputed since most lysoPL is bound to albumin, immuno-
globulins, and other plasma carrier systems, and levels are 
already higher than required for mediating GPCR activa-
tion.41–43 Importantly, recent cohort studies have shown that 
plasma lysoPC is inversely related to incidence of an event. 
These include Malmö, Bruneck, TwinGene, ULSAM, and 
PIVUS, which showed correlations of lower lysoPC with 
incident CHD risk, using untargeted lipidomics.31,44,45 Also, 
patients on hemodialysis show higher risk of a CHD event 
and elevated mortality with lower lysoPC.43 Lower lysoPCs 
are also associated with CHD factors such as visceral 
obesity, although since lysoPA cannot be measured using 
shotgun or untargeted methods, we have not found other 
cohort data that includes this lipid as yet.27,31,32 In the Bru-
neck cohort, inclusion of lysoPCs in classifiers improved 
power for CHD-risk prediction, indicating that although the 
reduction is rather modest, it is clinically significant.31 Fur-
thermore, the Malmö cohort reported that CHD develop-
ment is preceded by reduced levels of lysoPCs, around 8% 
similar to our data.44 In Malmö and Bruneck, the lipidomics 
was limited to untargeted and shotgun methods without 
further validation, thus our new data provides stronger ana-
lytical confidence while linking their findings to a specific 
risk locus. Given the prevalence of rs10757274 GG in the 
general population (≈23%), our data may at least, in part, 
explain the findings in other cohorts with lower lysoPLs 
now associating with a subgroup with a common SNP. 
In contrast, it is also known that elevations in long-chain 
unsaturated lysoPA maybe a feature of an acute cardiac 
event, where a sudden plaque rupture results in generation/
release, likely via activation of platelet phospholipases.18
In addition to lipid class-specific changes in PLs, many 
significantly decreased unknowns were found, which are 
currently absent in databases (Figure 1). The plasma 
lipidome contains large numbers of such species, and a 
significant challenge lies in their structural and biologi-
cal characterization. The comprehensive list of all lipids 
detected with fold change and significance levels is pro-
vided (Tab I in the Data Supplement) as a resource for 
further mining.
We next searched for potential mechanisms to explain the 
lipid changes using data sets from 2 cell models of ANRIL 
modulation because there is increasing evidence that this 
long noncoding RNA plays a central role in Chr9p21-linked 
cardiovascular disease (CVD). ANRIL is expressed by exons 
contained within Chr9p21, and there are many isoforms, 
including long, short, and circular, resulting from alternative 
splicing across several exons. Both increases and decreases 
of various ANRIL transcripts have been reported to be asso-
ciated with CVD. For example, compared with AA individuals, 
GG, and several other Chr9p12 risk SNPs have almost 50% 
lower ANRIL (exon 2) in peripheral blood cells.2 This agrees 
with the finding that multiple risk alleles are associated 
with a decrease in ANRIL (exons 1–2) in peripheral blood 
mononuclear cells.5 However, others showed various ANRIL 
transcripts are increased in carriers of risk alleles, including 
from exons 1 to 5, 7 to 13, and 18 to 19, with no change 
at exons 7b or 10 to 13b.3 Elsewhere, expression of short 
variants (exons 1–2, ending with alternative 13, and exons 
1, 5–7+13) were increased while long variants (coded by 
exons 1–12+14–20) were decreased in risk allele carri-
ers.6 In the VSMC data set used in our study, lines carry-
ing risk haplotypes (which were also GG for rs10757274) 
expressed higher levels of ANRIL transcripts (exon 6–7) 
compared with NNWT, which have a minimal expression, 
similar to a residual expression detected in KO lines.13 In 
contrast, the HEK inducible knockdown targeted proximal 
alternatively spliced ANRIL transcripts EU741058 (exons 1, 
5–7, and 13) and DQ485454 (exons 1–12 and alternative 
exon 13). Thus, while they both model human CVD they dif-
fer significantly in terms of their impact on ANRIL.
While it is known that ANRIL gene products regulate 
metabolic genes in cultured cells and stimulate VSMC 
proliferation while reducing adhesion and contraction, 
the impact of ANRIL on lysoPL/lysoPA metabolism is 
not characterized.12,13 Here, we showed in both HEK and 
VSMC data sets that there was a significant impact on a 
large number of lysoPL/lysoPA metabolism genes, with 
GO term analysis identifying a large number of lipid terms 
being significantly altered in HEK cells. In the case of 
VSMCs, removal of the risk locus indicated that several 
affected genes were directly influenced by the Chr9p21 
locus (Figure 5A and 5B). Our in-silico screen also iden-
tified 4 miRNAs across the cell types with 2 candidates 
identified from both HEK and VSMC lysoPL gene regu-
lation: miR-34a-5p (LPCAT3 and PLA2G6), miR-122-5p 
(LPCAT3 and PNPLA3). Collectively, this suggests that 
Chr9p21 risk alleles may alter lysoPL/lysoPA in humans 
via ANRIL regulation, providing novel insights into the 
biology of this important cause of CHD.
Many of the candidate genes are expressed in leuko-
cytes, platelets, erythrocytes, heart, adipose tissue, and 
plasma, thus measuring them in plasma is not possible. 
However, we could measure ATX (ENPP2), a plasma 
enzyme that converts primarily unsaturated lysoPC to 
lysoPA in healthy subjects.18 ATX protein was reduced, and 
furthermore, correlation analysis was consistent with lower 
ATX activity (Figures 2C and 3A through 3K), providing a 
potential explanation for lower lysoPAs in the GG group. 
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In line with this, ENPP2 expression negatively correlated 
with ANRIL (exons 18–19) in VSMC from the risk group, 
suggesting an association between this gene and a risk 
form of ANRIL (Figure IX in the Data Supplement). Also, 
ENPP2 was elevated in HEK cells, which lack ANRIL 
transcripts that contain exons 6 and 7. Furthermore, it has 
been reported that inflammatory cytokine induction of 
ENPP2 is suppressed by 50% in primary human mono-
cyte-derived macrophages that carry the Chr9p21 risk 
haplotype allele.46 The contribution of ATX to CHD is not 
understood and may vary with underlying genetic cause.47 
Indeed, while it metabolizes lysoPL to lysoPA in health, 
in acute coronary syndromes other pathways appear to 
predominate.18 This mirrors our suggestion that ATX might 
be less involved in plasmas with elevated CVD risk, with 
other uncharacterized pathways being relevant. Here, 
significant downregulation of ATX in GG plasma from 
middle-aged men who are otherwise healthy and without 
clinically detectable CHD was seen indicating it precedes 
cardiovascular events in this group (Figure 2C). While we 
suggest that reduced lysoPA maybe at least, in part, relate 
to reduced levels of plasma ATX, additional candidates 
were identified through transcriptional analysis, including 
PLPP1, PLPP2, PLPPR2 (all induced in HEK cells), or 
DGKA (reduced in RRWT VSMC cell lines).
In healthy subjects, lysoPLs, particularly lysoPC, cir-
culate at relatively high concentrations, where they could 
be generated by (1) lipases bound to the cell surface of 
endothelial cells in liver, heart, and adipose tissues (LPL, 
LIPC, and LIPG), (2) Land’s cycle enzymes in circulating 
blood cells/platelets,16 (3) lecithin-cholesterol acyl trans-
ferase (LCAT) trans-esterification in the liver, or (4) by 
remodeling pathways for PAF (platelet-activating factor) 
removal (Figure 6). In healthy tissue, lipases predomi-
nate but during vascular inflammation the balance may 
alter, but this is not well characterized. The Land’s cycle 
involves phospholipase A2 hydrolysis, although the iso-
forms controlling blood levels are not fully known. Can-
didates include stromal isoforms and cellular or secreted 
phospholipase A2 from circulating cells and platelets 
that may become relevant during inflammation. Also, a 
role for circulating/platelet phospholipase A1 from plate-
lets in lysoPL formation has been proposed.40 The reduc-
tion in lysoPCs is consistent with significantly different 
genes identified in the data sets, for example, ACSL6, 
MBOAT2, LPCAT2, PLBD1 (all induced in HEK cells), 
PNPLA2 and PLA2G4C (downregulated in HEK cells), 
and PLA2G12A and LCAT (reduced in RRWT VSMC 
cell lines). Notably, the transcriptional data sets showed 
complex and largely different changes in lysoPL gene 
expression, which may relate to them being from differ-
ent cell types, and with different manipulations to ANRIL 
isoform expression. However, 4 genes were significantly 
altered across both data sets: MBOAT2 and LPL (always 
upregulated) and DGKA, PLPP1 (increased in HEK, 
decreased in VSMC). A detailed discussion of the known 
expression patterns and roles of all these genes is pro-
vided in Material in the Data Supplement.
Notably, many of the genes found to be altered in the 
transcriptional data are genes with known SNPs that cor-
relate with traditional lipid measures. For many of these 
genes, it is not clear how or even if they regulate lipid 
levels directly or are simply associated with altered levels 
(in the case of traditional lipids). Cardiovascular disease 
is complex with different forms, however, in the case of 
Chr9p21-linked CHD, a strong phenotype of coronary 
artery disease is noted.48 Similarly, traditional lipid levels are 
also strongly associated with a strong phenotype of coro-
nary artery disease. This indicates that clinical outcomes are 
similar despite the different genetic origins and for this to 
be the case, some convergence in biochemical or cellular 
pathways downstream of genetics would be expected. A 
potential explanation for our findings is that downstream of 
ANRIL, some of the same genes that are already known to 
be genetically associated with CHD are subtly altered at 
their gene expression levels through transcriptional mecha-
nisms, such as proposed here (eg, miRNA sponge activities 
of ANRIL), and that this then goes on to impact inflam-
mation. This would promote the development of coronary 
artery disease, through some common mechanisms, inde-
pendent of the biology of traditional lipoprotein measures. 
While several genes were found to be altered in either 
the HEK or VCMC data sets, more research is required to 
link gene expression changes with lysoPC/lysoPA levels, 
including protein and enzyme activity measurements from 
carriers of Chr9p21 risk SNPs. LysoPCs and lysoPAs are 
metabolized in a complex manner, with many gene products 
in the vasculature expected to play a contributing role. It is 
also the case that standard lipids are metabolized in a com-
plex manner and that changes in one relevant gene could 
be compensated by changes in others, that overall lead to 
standard lipids such as triglycerides and cholesteryl esters 
being overall unchanged in these subjects.
We also note that many genes in the HEK or VSMC 
analysis changed in directions that on their own could 
be considered to predict increases in lysoPC/lysoPA. 
However, overall it is the combination/balance of sev-
eral enzymatic activities that will determine the flux of 
lipids through this pathway, and thus, their overall lev-
els at steady state. Thus, changes in some could be 
over-compensated by changes in others, leading to the 
observed phenotype of overall reduced levels of these 
lipids. For further reference, genes with SNPs that have 
been found to associate with standard lipid traits and 
were also found to change herein are listed in.49,50
A final question relates to how ANRIL and lysoPLs 
are functionally connected. PL metabolism is finely 
tuned during cell proliferation, with higher concentra-
tions of lysoPC and lysoPE detected at G2/M, which fall 
dramatically along with concomitant increases in PC/
PE due to acylation during progression to G1.51 This 
provides the PL membranes required to complete the 
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Figure 6. Metabolic pathway showing lysoPL (lysophosphospholipids)/lysoPA (lysophosphatidic acid) regulatory genes that 
are significantly altered by ANRIL knockdown in HEK cells.
Genes that metabolize these lipids are shown. Full data on their transcriptional regulation is provided in Table 3, Tab VII in the Data 
Supplement. LCAT was not significantly regulated but is shown for completeness.
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cell cycle. Given ANRIL’s ability to regulate cell prolif-
eration and observations that silencing ANRIL prevents 
division and promotes senescence, the lower levels of 
lysoPLs in plasma may simply reflect altered rates of 
cell turnover in the vasculature, but this remains to be 
determined (Figure 5C and 5D). Here, 4 miRNAs known 
to be regulated by ANRIL that also suppress expres-
sion of selected lysoPL genes across both HEK and 
VSMC data sets were found miR-186-3p, miR-34a-3p, 
miR-122-5p, and miR-34a-5p. These potential hits can 
be followed up as candidate downstream mediators of 
ANRIL’s regulation of lysoPL/lysoPA metabolism. Sev-
eral have well-known roles in regulating proliferation 
and notably circulating miR-122-5p associates with 
acute myocardial infarction.52
In summary, we reveal an association of altered 
PL metabolism with CHD risk in a common risk SNP. 
The alterations in multiple lysoPL/lysoPA regulatory 
pathways seen on ANRIL silencing, or the presence/
removal of the risk locus in vitro, further suggest the 
involvement of bioactive signaling lipids in this form 
of vascular disease, and mechanistic studies are war-
ranted. To this end, fresh blood from AA and GG sub-
jects is required to measure plasma and cellular levels 
of all candidate enzymes and relevant lipids, to iden-
tify how lysoPC/lysoPA metabolism is altered by the 
presence of the risk SNP. It would also be important to 
compare AG with AA and GG subjects (also including 
women) and also those who go on to have events. How-
ever, for this considerably larger sample numbers would 
be required than we have available currently in NPHSII. 
Furthermore, if heparin is administered to subjects then 
LPL, LIPC, LIPG enzymes would be released and could 
be measured in plasma.
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